- Home
-
Press releases
-
Media academy
- Lung Cancer
- Breast Cancer
- Ovarian Cancer
- Head & Neck Cancer
- Targeted Therapy
Boehringer Ingelheim
Cell-cycle kinases are proteins that control a cell’s passage through cell division. Polo-like kinases (Plk) are members of a family of serine/threonine kinases that are important regulators of cell cycle progression. Plk1 is the best characterised of the four known human Plks and is only expressed in tissues with proliferative potential such as placental, endometrial, bone marrow and malignant tumour tissue. In many human cancers, high expression of Plk1 is thought to be associated with invasive growth and poor prognosis. Plk1 therefore represents an attractive target for therapeutic intervention.
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.
